Skip to content

A randomized controlled study on the reduction of artery-recessive blood loss in senile intertrochanteric fracture

A randomized controlled study on the reduction of artery-recessive blood loss in senile intertrochanteric fracture

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017761
Enrollment
Unknown
Registered
2018-08-13
Start date
2018-09-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elderly intertrochanteric fracture

Interventions

TXA group:TXA intervention
Control group:Equal saline intravenous intervention

Sponsors

Chongqing General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: Radiographic examination (CR, CT, MRI, etc.) confirmed the initial fresh intertrochanteric fracture of the femur. The age was more than 65 years old, and the injury time was close to 6h.

Exclusion criteria

Exclusion criteria: Time of injury >6h patients; Open fractures or bleeding wounds in other parts of the body or bleeding diseases in other parts of the body (such as gastrointestinal bleeding); Combined with fresh fractures in other parts; Patients with coagulopathy; Blood color doppler ultrasound examination on admission found thrombosis in deep vein of lower limbs, or previous history of thromboembolism; Pulmonary infection or other infection, infection is not effectively controlled; Patients with serious diseases such as heart, brain and lung; It has always been clear that patients with hypersensitivity or hypersensitivity to aminocyclic acid should be combined with the whole body of the patient before applying it, and the adverse reactions should be timely treated by referring to the instructions of the drug for aminocyclic acid or the Chinese pharmacopoeia.

Design outcomes

Primary

MeasureTime frame
HGB;HCT;Hidden Blood loss;Proportion of transfused patients;The incidence of deep vein thrombosis and pulmonary embolism;

Secondary

MeasureTime frame
Coagulation function test;

Countries

China

Contacts

Public ContactMa HuiXu

Chongqing General Hospital

mahuixu@aliyun.com+86 13512363345

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026